Novo Nordisk plans to cut Ozempic and Wegovy prices by up to 50% starting in 2027. The new list price will be $675 monthly, aimed at improving access. Despite the move to boost affordability, shares fell nearly 3% in pre-market trading. Retail sentiment, however, remains bullish.